Market Research Logo

Cardiac Biomarkers: Technologies and Global Markets

Cardiac Biomarkers: Technologies and Global Markets

Report Scope

The principal objectives of this report are to:
- Identify viable technology drivers through a comprehensive look at various platform technologies for cardiac marker segments of the diagnostic testing market.
- Obtain a complete understanding of the leading cardiac markers and their value in terms of diagnostic testing, screening, prognostic monitoring, pharmacogenomic testing, and theranostics, while also appreciating these elements from their basic principles to their applications.
- Discover feasible market opportunities via identification of high-growth applications in different cardiac marker diagnostic testing areas, with a focus on the biggest and fastest-expanding markets for diseases.
- Focus on global industry development through an in-depth analysis of the major world markets for cardiac marker diagnostic testing, including forecasts for growth.
- Present market figures for the current value of the cardiac marker testing market, projections and growth rates. These are taken from the most recently available from the global diagnostics industry.

By purchasing this study, the reader will gain:
- An improved understanding of the current state and future of the most exciting cardiac marker diagnostic testing market segments.
- The latest information on the leading companies engaged in research and development (R&D) and products in the cardiac marker diagnostic reagent pipeline with SWOT analyses.
- A leading perspective of recent diagnostic test developments and revelations as well as knowledge of how they will influence selected clinical markets.
- Knowledge of the cardiac diagnostic testing market as an area of growth, research and investment.

This analysis covers the following categories of the cardiac diagnostic testing segments:
- AMI.
- Heart failure.
- Brain natriuretic peptide (BNP).
- Myoglobin.
- Homocysteine (Hcy).
- C-reactive protein (CRP).
- Pulmonary embolism (PE) D-dimer test.
- Low-density lipoproteins (LDL) and high-density lipoproteins (HDL).
- Stroke.
- Creatine kinase-myocardial band (CK-MB) and cardiac enzymes.
- Albumin.
- Cardiac markers used in clinical decisions.
- Cardiac markers in renal failure.
- Troponins in non-ischemic heart disease.
- Cardiac panels.
- POC cardiac markers.

Analyses include charts and graphs measuring product growth and trends within the marketplace. In addition, a discussion of research on various illnesses provides the reader with a deeper understanding of the possibilities for future treatment and avenues for possible R&D budgets. Company-specific information, including sales figures, product pipeline status and R&D trends, is provided throughout the report. In addition, the study:

- Assesses cardiac marker diagnostic testing market drivers and bottlenecks from the perspective of the medical and scientific communities.
- Discusses the potential benefits of the cardiac marker diagnostic testing market for various sectors of the medical and scientific community.
- Establishes the current total market size and future growth of the cardiac marker diagnostic testing market and analyzes the current size and growth of individual segments.
- Provides current and forecasted market shares by company.
- Discusses profit and business opportunities by diagnostic testing segment.
- Provides strategic recommendations for near-term business opportunities.
- Assesses current commercial uses of the cardiac marker diagnostic testing market.

Report Includes

- 64 data table and 40 additional tables
- An overview of the global market for cardiac biomarkers and related technologies
- Analyses of global market trends, with data from 2016 to 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Classification of cardiac biomarkers by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease
- Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT)
- Examination of the technology regarding diagnostic methods, instrumentation, newly issued patents, and new patent applications
- Coverage of clinical guidelines and government regulations
- Comprehensive company profiles of major Players in the Market including Abbott Laboratories, Biomérieux S.A., Bio-Rad Laboratories Inc, Life Diagnostics Inc., Meridian Life Science Inc. Randox Laboratories Ltd., Roche, Sanyo Chemical Industries Ltd., Siemens Ag, and Thermo Fisher Scientific Inc.


Chapter 1 Introduction
Scope of the Report
Methodology and Information Sources
Primary Data and Information Gathering
Secondary Data and Information Gathering
Market Share Analysis and Market Forecast Prediction
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Cardiovascular Disease and Burden of Cardiovascular Disease
Overview of Cardiovascular Disease
Coronary Artery Disease
Atherosclerosis
Angina (Angina Pectoris)
Acute Myocardial Infarction
Disease Management
Medical Management
Lifestyle Changes
Diet Modification
Smoking Cessation
Pharmaceuticals
Anticoagulants and Antiplatelet Drugs
Lipid-Lowering Drugs
Anti-Hypertensive Drugs
Nitroglycerin Preparations
Surgical Intervention
The Global Burden of Cardiovascular Disease
Global Burden of Cardiovascular Disease, 2015
2030 Global Burden of Cardiovascular Disease
The Global Economic Burden of Cardiovascular Disease
Chapter 4 Introduction to Cardiac Biomarkers
Types of Biomarkers
Antecedent Biomarker Tests
Screening Biomarker Tests
Diagnostic Biomarker Tests
Staging Biomarkers
Prognostic Biomarker Tests
Role of Biomarkers in the Prevention, Assessment and Management of Heart Failure
Myocardial Stress/Injury
Neurohormonal Activation
Remodeling
Comorbidities
Other Biomarkers of Cardiac Activity
Their Role of Biomarkers in Heart Failure Clinical Trials
Biomarker Discovery and Validation
Biomarker Candidate Screening
Biomarker Candidate Validation
Omic Technologies for Biomarker Discovery
Genomics
Proteomics
Metabolomics
Lipidomics
Considerations When Developing a Cardiac Biomarker
Defining Abnormal Biomarker Values
Reference Limits
Discrimination Limits
Threshold Defining Risk
Receiver Operating Characteristic Curve Analysis of Biomarker Accuracy
Chapter 5 Review of Key Individual Cardiac Biomarkers
Gold Standard of Cardiac Biomarkers
Troponin Complex
Troponin C
Troponin T
Troponin I
Troponin as the Preferred Biomarker
High Sensitivity Troponin Assays
Emergence of Point-of-Care Troponin Testing
Pro-BNP and/or NT-proBNP
Creatine Kinase Test
Myoglobin (Mb)
C-Reactive Protein
Other Key Cardiac Biomarkers
Copeptin
D-dimer
Galectin-3
Fatty Acid Binding Proteins
ST2
Emerging Cardiac Biomarkers
Choline
Ischemia-Modified Albumin
Myeloperoxidase
S100-beta
Recent Technological Advances and Key Developments in Cardiac Biomarker Measurement
Chapter 6 Global Cardiac Biomarker Market Analysis
Introduction
Global Cardiac Biomarker Market by Cardiac Biomarker Type
Regional Overview
North American Cardiac Biomarker Market Analysis
Selected Drivers of the North American Cardiac Biomarker Market
Selected Restraints of the North American Cardiac Biomarker Market
North American Cardiac Biomarker Market, by Country
European Cardiac Biomarker Market Analysis
Selected Drivers of the European Cardiac Biomarker Market
Selected Restraints of the European Cardiac Biomarker Market
European Cardiac Biomarker Market, by Country
Asia-Pacific Cardiac Biomarker Market Analysis
Selected Drivers of the Asia-Pacific Cardiac Biomarker Market
Selected Restraints of the Asia-Pacific Cardiac Biomarker Market
Asia-Pacific Cardiac Biomarker Market by Country
Central and Latin American Cardiac Biomarker Market Analysis
Selected Drivers of the Central and Latin American Cardiac Biomarker Market
Selected Restraints of the Central and Latin American Cardiac Biomarker Market
Central and Latin American Cardiac Biomarker Market by Country
Middle East and African Cardiac Biomarker Market Analysis
Selected Drivers of the Middle East and African Cardiac Biomarker Market
Selected Restraints of the Middle East and African Cardiac Biomarker Market
Middle East and African Cardiac Biomarker Market by Region
Cardiac Biomarker Market Shares by Geographic Region
Global Market Share Analysis
Chapter 7 Regulatory and Legislative Requirements for Cardiac Biomarkers
North America
United States
Recent Developments
Canada
Europe
(General) Medical Device Directive, MDD (93/42/EEC)
Active Implantable Medical Device Directive, AIMDD (90/383/EEC)
In Vitro Diagnostic Medical Device Directive, IVDMDD (98/79/EC)
Proposed Changes to the Medical Device Directive, MDD (93/42/EEC)
Notified Bodies
German Reimbursement Structure and Schedules for Diagnostic Procedures
French Reimbursement Structure and Schedules for Diagnostic Procedures
Italian Reimbursement Structure and Schedules for Diagnostic Procedures
Japan
Marketing Authorization System
China
Overview of the Healthcare System
Healthcare Reforms
Healthcare Institutions
India
Overview of the Healthcare System
Hospital Resources
Population Statistics
South Korea
Brazil
Background
Regulatory and Legislative Requirements
Market Entry and Reimbursement of Medical Devices
Argentina
Background
Mexico
Legislation and Regulations Governing Medical Devices in Mexico
Health Insurance Structure
Chapter 8 Patent Review and New Developments for Cardiac Biomarkers
Introduction
Cardiac Biomarker Patents by Region and Country
Chapter 9 Company Profiles
ABBOTT LABORATORIES
ACS BIOMARKER BV
BECKMAN COULTER (PART OF DANAHER)
BG MEDICINE INC.
BIOMERIEUX S.A.
BIO-RAD LABORATORIES INC.
CARDIOGENICS
CAVADIS
CRITICAL DIAGNOSTICS
CRUINN MEDICAL LTD.
HEALTH-CHEM DIAGNOSTICS
LIFE DIAGNOSTICS INC.
LIFESIGN
LSI MEDIENCE CORP.
MERIDIAN LIFE SCIENCE INC.
METANOMICS HEALTH GMBH
MIRNEXT
ORTHO-CLINICAL DIAGNOSTICS INC.
PTS DIAGNOSTICS
RADIOMETER MEDICAL APS
RANDOX LABORATORIES LTD.
RESPONSE BIOMEDICAL CORP.
ROCHE (FORMERLY HOFFMANN-LA ROCHE LTD.)
SANYO CHEMICAL INDUSTRIES LTD.
SIEMENS AG
SINGULEX INC.
SPECTRAL MEDICAL, INC.
THERMO FISHER SCIENTIFIC
TOSOH BIOSCIENCE INC.
TRINITY BIOTECH PLC
ZENOSENSE INC.
Chapter 10 Appendix A: Company Addresses and Contact Details
Company Addresses and Contact Details
Chapter 11 Appendix B: Government Regulatory Agencies and Professional Organizations
Government Regulatory Agencies and Professional Organizations
Chapter 12 Appendix C: Commonly Used Acronyms Associated with Cardiac Biomarkers
List of Tables
Summary Table A : Global Cardiac Biomarker Market, by Biomarker Type, Through 2022
Summary Table B : Global Cardiac Biomarker Market Share, by Region, 2017
Table 1 : Standard Angina Pectoris Classification
Table 2 : Top 20 Leading Causes of Death, 2015
Table 3 : Estimated Deaths Due to Noncommunicable Diseases, by Sex and Disease, 2015
Table 4 : Estimated Deaths Due to Cardiovascular Disease, by Sex and Disease, 2015
Table 5 : Global Health Estimates, by Sex and WHO Region, 2015
Table 6 : Estimated Deaths Due to Cardiovascular Disease, by Sex and Disease, 2030
Table 7 : Estimated Deaths Due to Cardiovascular Disease, by Sex and WHO Region, 2030
Table 8 : Economic Burden of NCDs in India, 2012-2030
Table 9 : Summary of Heart Failure Biomarkers
Table 10 : Cardiac Biomarkers of Myocyte Stretch
Table 11 : Cardiac Biomarkers of Myocyte Injury
Table 12 : Cardiac Biomarkers of Oxidative Stress
Table 13 : Cardiac Biomarkers of Neurohormonal Activation
Table 14 : Prognostic and Diagnostic Values and Analytical Performance of Inflammatory Markers in Coronary Artery Disease
Table 15 : Cardiac Biomarkers of Inflammation and Atherogenesis
Table 16 : Cardiac Biomarkers of Renal Dysfunction
Table 17 : Soluble Cell Adhesion Molecules
Table 18 : Cardiac Biomarkers of Thrombosis
Table 19 : Cardiac Biomarkers of Metabolic/Lipid Dysregulation
Table 20 : Cardiac Biomarkers of Brain Damage
Table 21 : Techniques Available for Biomarker Development
Table 22 : Desirable Features of Cardiac Biomarkers
Table 23 : Common Cardiac Biomarkers
Table 24 : Contemporary Cardiac Troponin I and T Assay Analytical Characteristics as Designated by the Manufacturer
Table 25 : High Sensitivity* Cardiac Troponin I and T Assay Analytical Characteristics Designated by Manufacturer
Table 26 : Point-of-Care Cardiac Troponin I and T Assay Analytical Characteristics Designated by Manufacturer
Table 27 : BNP, NT-proBNP and MR-proANP Assays: Analytical Characteristics Designated by Manufacturer
Table 28 : Profile of Biomarker Myoglobin
Table 29 : Profile of Biomarker ST2
Table 30 : Global Cardiac Biomarker Market, Through 2022
Table 31 : Global Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 32 : Global Cardiac Biomarker Market Share, by Biomarker Type, 2017
Table 33 : Global Cardiac Biomarker Market Share, by Region, 2017
Table 34 : Global Cardiac Biomarker Market, by Region, 2017
Table 35 : Global Cardiac Biomarker Market, by Instrument Category, Through 2022
Table 36 : North American Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 37 : North American Cardiac Biomarker Market, by Instrument Category, Through 2022
Table 38 : Projections of Crude CVD Prevalence in the United States, 2010-2030
Table 39 : North American Cardiac Biomarker Market Share, by Country, 2017
Table 40 : United States Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 41 : Canadian Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 42 : European Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 43 : European Cardiac Biomarker Market, by Instrument Category, Through 2022
Table 44 : European Cardiac Biomarker Market Share, by Country, 2017
Table 45 : French Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 46 : German Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 47 : Italian Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 48 : Spanish Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 49 : United Kingdom Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 50 : Benelux Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 51 : Scandinavian Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 52 : Rest of Europe Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 53 : Asia-Pacific Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 54 : Asia-Pacific Cardiac Biomarker Market, by Instrument Category, Through 2022
Table 55 : Asia-Pacific Cardiac Biomarker Market Share, by Country, 2017
Table 56 : Japanese Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 57 : Chinese Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 58 : Indian Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 59 : South Korean Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 60 : Rest of Asia-Pacific Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 61 : Central and Latin American Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 62 : Central and Latin American Cardiac Biomarker Market, by Instrument Category, Through 2022
Table 63 : Central and Latin American Cardiac Biomarker Market Share, by Country, 2017
Table 64 : Argentinian Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 65 : Brazilian Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 66 : Chilean Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 67 : Mexican Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 68 : Rest of Central and Latin American Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 69 : Middle East and African Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 70 : Middle East and African Cardiac Biomarker Market, by Instrument Category, Through 2022
Table 71 : Middle East and African Cardiac Biomarker Market Share, by Region, 2017
Table 72 : Middle Eastern Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 73 : African Cardiac Biomarker Market, by Biomarker Type, Through 2022
Table 74 : Global Cardiac Biomarker Market Share, by Company, 2017
Table 75 : North American Cardiac Biomarker Market Share, by Company, 2017
Table 76 : European Cardiac Biomarker Market Share, by Company, 2017
Table 77 : Asia-Pacific Cardiac Biomarker Market Share, by Company, 2017
Table 78 : Latin and Central American Cardiac Biomarker Market Share, by Company, 2017
Table 79 : Middle East and African Cardiac Biomarker Market Share, by Company, 2017
Table 80 : ICD-9 and ICD 10 CM Diagnosis Codes Commonly Used to Report Cardiac Conditions
Table 81 : Clinical Diagnostic Laboratory Fee Schedule, 2018
Table 82 : Comparison of Pharmaceutical Affair Law and Japanese Medical Device Nomenclature and Related Codes with the EU MDD
Table 83 : Number of Healthcare Institutions According to Ownership in China, 2010
Table 84 : Total Number of Hospitals by Ranking in China, 2010
Table 85 : Overview of Healthcare in India
Table 86 : Recent Canadian Patent Publications Relating to Cardiac Biomarkers
Table 87 : Recent Chinese Patent Publications Relating to Cardiac Biomarkers
Table 88 : Recent European Patent Publications Relating to Cardiac Biomarkers
Table 89 : Recent Eastern European Patent Publications Relating to Cardiac Biomarkers
Table 90 : Recent U.S. Patent Publications Relating to Cardiac Biomarkers
Table 91 : Recent Asia-Pacific Patent Publications Relating to Cardiac Biomarkers
Table 92 : Recent Global Patent Publications Relating to Cardiac Biomarkers
Table 93 : Abbott Laboratories’ Revenue, by Business Segment, 2014-2016
Table 94 : Danaher’s Revenue, by Business Segment, 2014-2016
Table 95 : BioMérieux S.A.’s Sales, by Application, 2015 to 2016
Table 96 : Bio-Rad Laboratories Inc.’s Revenue, by Business Segment, 2014-2016
Table 97 : Roche Group’s Revenue, by Business Segment, 2014-2016
Table 98 : Roche Group’s Revenue, by Diagnostic Segment, 2014-2016
Table 99 : Siemens AG Cardiovascular Assay Menu
Table 100 : Thermo Fisher Scientific’s Revenue, by Business Segment, 2014-2016
Table 101 : Thermo Fisher Scientific’s Results of Operations, by Region, 2014-2016
Table 102 : Company Addresses and Contact Details
Table 103 : Government Regulatory Agencies and Professional Organizations Associated with Cardiac Biomarkers
Table 104 : Commonly Used Acronyms Associated with Cardiac Biomarkers
List of Figures
Summary Figure A : Global Cardiac Biomarker Market Share, by Biomarker Type, 2017
Summary Figure B : Global Cardiac Biomarker Market Share, by Region, 2017
Figure 1 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age, 2015
Figure 2 : Global Distribution of Male Deaths Caused, by Cardiovascular Disease, 2015
Figure 3 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, by Age, 2015
Figure 4 : Global Distribution of Female Deaths Caused, by Cardiovascular Disease, 2015
Figure 5 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age, 2030
Figure 6 : Global Distribution of Male Deaths Caused, by Cardiovascular Disease, 2030
Figure 7 : Global Distribution of Female Deaths Caused, by Cardiovascular Disease, by Age, 2030
Figure 8 : Global Distribution of Female Deaths Caused, by Cardiovascular Disease, 2030
Figure 9 : Projected Total Costs of Cardiovascular Disease in The United States, 2015-2030
Figure 10 : Classes of Biomarkers Contributing to the HF Biomarker Profile
Figure 11 : Possible Roles of C-Reactive Protein in the Pathogenesis of Metabolic Syndrome and Cardiovascular Disorders
Figure 12 : Biomarker Use in Heart Failure Trials
Figure 13 : Approaches to Defining Abnormal Biomarker Values
Figure 14 : Receiver Operating Characteristic Curve in Different Cardiac Biomarkers
Figure 15 : Interpreting Elevated Levels of Cardiac Troponin
Figure 16 : Comparison of 19 Cardiac Troponin Assays
Figure 17 : Schematic Diagram of the Synthesis of NT-proBNP and BNP from the Pre-proBNP Protein by Cardiomyocytes
Figure 18 : Interpretation of NT-proBNP Values as a Predictor of Heart Failure
Figure 19 : Global Cardiac Biomarker Market Share, by Biomarker Type, 2017
Figure 20 : Global Cardiac Biomarker Market Share, by Region, 2017
Figure 21 : North American Cardiac Biomarker Market, by Biomarker Type, 2017
Figure 22 : North American Cardiac Biomarker Market Share, by Country, 2017
Figure 23 : United States Cardiac Biomarker Market, by Biomarker Type, 2017
Figure 24 : European Cardiac Biomarker Market, by Biomarker Type, 2017
Figure 25 : European Cardiac Biomarker Market Share, by Country, 2017
Figure 26 : Asia-Pacific Cardiac Biomarker Market, by Biomarker, 2017
Figure 27 : Asia-Pacific Cardiac Biomarker Market Share, by Country, 2017
Figure 28 : Central and Latin American Cardiac Biomarker Market, by Biomarker Type, 2017
Figure 29 : Central and Latin American Cardiac Biomarker Market Share, by Country, 2017
Figure 30 : Middle East and African Cardiac Biomarker Market, by Biomarker Type, 2017
Figure 31 : Middle East and African Cardiac Biomarker Market Share, by Region, 2017
Figure 32 : Private Health Insurance Coverage for U.S. Residents under 65, 2007-2011
Figure 33 : Illustration of Medicare Payment Process
Figure 34 : French Pricing and Reimbursement Process for Medical Devices
Figure 35 : Market Access Pathway for Inpatient Medical Devices in Italy
Figure 36 : Market Access Pathway for Outpatient Medical Devices in Italy
Figure 37 : The Chinese Healthcare System

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report